Dihydropyridine calcium antagonists selectively inhibit calcium ions from entering smooth muscle cells and myocardial cells across the membrane, thereby reducing peripheral vascular resistance and lowering blood pressure. They can also reduce myocardial oxygen demand and relieve angina pectoris. They do not affect plasma calcium concentration, and long-term use does not cause significant changes in heart rate or plasma catecholamines.

It is rapidly converted into the antiviral compound penciclovir in the body, which has an inhibitory effect on herpes simplex virus type Ⅰ (HSV-1), herpes simplex virus type Ⅱ (HSV-2) and varicella zoster virus (VZV). Penciclovir triphosphate inhibits the activity of HSV-2 polymerase by competing with guanosine triphosphate, thereby selectively inhibiting the synthesis and replication of herpes virus DNA.

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. Its effect on Gram-positive bacteria is slightly worse than that of erythromycin, and its effect on Legionella pneumophila is stronger than that of erythromycin. Its antimicrobial effect on Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P position), blocking the transfer RNA (t-RNA) from binding to the P position, and also blocking the transfer of the polypeptide chain from the acceptor position (A position) to the P position, thereby inhibiting bacterial protein synthesis.

This product is a methylhydroxyglutaryl coenzyme A (HMG-COA) reductase inhibitor, which inhibits the synthesis of endogenous cholesterol and is a blood lipid regulator. It has the effect of reducing the cholesterol (TC) content in the serum, liver, and aorta of hyperlipidemia rabbits, and reducing the levels of very low density lipoprotein cholesterol (VLDL-C) and low density lipoprotein cholesterol (LDL-C).

Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including: Gram-positive aerobic bacteria, Staphylococcus aureus, Streptococcus pyogenes (group A beta; hemolytic streptococci), pneumonia (streptococci), a-hemolytic streptococci (grass-green streptococci) and other streptococci, diphtheria (rod-shaped) bacilli. This product shows cross-resistance to erythromycin-resistant Gram-positive bacteria, including fecal streptococci (enterococci) and various methicillin-resistant Staphylococcus strains.